BEAM-302 shows durable efficacy and safety in AATD
BEAM-302 showed durable, one-time correction of AAT biology in AATD patients, achieving protective AAT levels, reducing disease-driving Z-AAT, and maintaining a favorable safety profile. Regulatory alignment supports an accelerated approval pathway.